vs
Apellis Pharmaceuticals, Inc.（APLS）与SPORTSMAN'S WAREHOUSE HOLDINGS, INC.（SPWH）财务数据对比。点击上方公司名可切换其他公司
SPORTSMAN'S WAREHOUSE HOLDINGS, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$331.3M vs $199.9M），SPORTSMAN'S WAREHOUSE HOLDINGS, INC.净利率更高（0.0% vs -29.5%，领先29.5%），SPORTSMAN'S WAREHOUSE HOLDINGS, INC.同比增速更快（2.2% vs -5.9%），SPORTSMAN'S WAREHOUSE HOLDINGS, INC.自由现金流更多（$8.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -5.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
运动员仓库控股（Sportsman's Warehouse）是美国户外体育用品零售商，门店遍布全美29个州，主要面向狩猎、射击、露营、垂钓等各类户外休闲运动爱好者，销售户外服饰、鞋履及专业运动装备。
APLS vs SPWH — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $331.3M |
| 净利润 | $-59.0M | $8.0K |
| 毛利率 | — | 32.8% |
| 营业利润率 | -25.6% | 1.3% |
| 净利率 | -29.5% | 0.0% |
| 营收同比 | -5.9% | 2.2% |
| 净利润同比 | -62.2% | -97.8% |
| 每股收益（稀释后） | $-0.40 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $331.3M | ||
| Q3 25 | $458.6M | $293.9M | ||
| Q2 25 | $178.5M | $249.1M | ||
| Q1 25 | $166.8M | $340.4M | ||
| Q4 24 | $212.5M | $324.3M | ||
| Q3 24 | $196.8M | $288.7M | ||
| Q2 24 | $199.7M | $244.2M | ||
| Q1 24 | $172.3M | $370.4M |
| Q4 25 | $-59.0M | $8.0K | ||
| Q3 25 | $215.7M | $-7.1M | ||
| Q2 25 | $-42.2M | $-21.3M | ||
| Q1 25 | $-92.2M | $-8.7M | ||
| Q4 24 | $-36.4M | $-364.0K | ||
| Q3 24 | $-57.4M | $-5.9M | ||
| Q2 24 | $-37.7M | $-18.1M | ||
| Q1 24 | $-66.4M | $-8.7M |
| Q4 25 | — | 32.8% | ||
| Q3 25 | — | 32.0% | ||
| Q2 25 | — | 30.4% | ||
| Q1 25 | — | 30.4% | ||
| Q4 24 | — | 31.8% | ||
| Q3 24 | — | 31.2% | ||
| Q2 24 | — | 30.2% | ||
| Q1 24 | — | 26.8% |
| Q4 25 | -25.6% | 1.3% | ||
| Q3 25 | 48.7% | -1.1% | ||
| Q2 25 | -18.6% | -7.9% | ||
| Q1 25 | -50.0% | 1.1% | ||
| Q4 24 | -12.3% | 1.0% | ||
| Q3 24 | -24.0% | -1.5% | ||
| Q2 24 | -14.7% | -8.4% | ||
| Q1 24 | -36.0% | -2.1% |
| Q4 25 | -29.5% | 0.0% | ||
| Q3 25 | 47.0% | -2.4% | ||
| Q2 25 | -23.6% | -8.5% | ||
| Q1 25 | -55.3% | -2.6% | ||
| Q4 24 | -17.1% | -0.1% | ||
| Q3 24 | -29.2% | -2.0% | ||
| Q2 24 | -18.9% | -7.4% | ||
| Q1 24 | -38.5% | -2.4% |
| Q4 25 | $-0.40 | $0.00 | ||
| Q3 25 | $1.67 | $-0.18 | ||
| Q2 25 | $-0.33 | $-0.56 | ||
| Q1 25 | $-0.74 | $-0.22 | ||
| Q4 24 | $-0.30 | $-0.01 | ||
| Q3 24 | $-0.46 | $-0.16 | ||
| Q2 24 | $-0.30 | $-0.48 | ||
| Q1 24 | $-0.54 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $2.2M |
| 总债务越低越好 | — | $44.0M |
| 股东权益账面价值 | $370.1M | $209.5M |
| 总资产 | $1.1B | $913.9M |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $2.2M | ||
| Q3 25 | $479.2M | $1.8M | ||
| Q2 25 | $370.0M | $3.6M | ||
| Q1 25 | $358.4M | $2.8M | ||
| Q4 24 | $411.3M | $2.7M | ||
| Q3 24 | $396.9M | $2.6M | ||
| Q2 24 | $360.1M | $2.2M | ||
| Q1 24 | $325.9M | $3.1M |
| Q4 25 | — | $44.0M | ||
| Q3 25 | — | $43.9M | ||
| Q2 25 | — | $24.1M | ||
| Q1 25 | — | $24.1M | ||
| Q4 24 | — | $24.0M | ||
| Q3 24 | — | $24.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $209.5M | ||
| Q3 25 | $401.2M | $208.9M | ||
| Q2 25 | $156.3M | $215.1M | ||
| Q1 25 | $164.2M | $235.7M | ||
| Q4 24 | $228.5M | $243.6M | ||
| Q3 24 | $237.1M | $243.0M | ||
| Q2 24 | $264.3M | $247.5M | ||
| Q1 24 | $266.7M | $264.6M |
| Q4 25 | $1.1B | $913.9M | ||
| Q3 25 | $1.1B | $948.9M | ||
| Q2 25 | $821.4M | $929.7M | ||
| Q1 25 | $807.3M | $852.1M | ||
| Q4 24 | $885.1M | $967.7M | ||
| Q3 24 | $901.9M | $901.9M | ||
| Q2 24 | $904.5M | $930.4M | ||
| Q1 24 | $831.9M | $886.2M |
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $16.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 2.6% |
| 资本支出强度资本支出/营收 | 0.1% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 2038.00× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-39.7M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $16.3M | ||
| Q3 25 | $108.5M | $-26.6M | ||
| Q2 25 | $4.4M | $-60.2M | ||
| Q1 25 | $-53.4M | $52.8M | ||
| Q4 24 | $19.4M | $-2.5M | ||
| Q3 24 | $34.1M | $18.5M | ||
| Q2 24 | $-8.3M | $-34.6M | ||
| Q1 24 | $-133.0M | $68.9M |
| Q4 25 | $-14.3M | $8.7M | ||
| Q3 25 | $108.3M | $-33.9M | ||
| Q2 25 | $4.4M | $-64.0M | ||
| Q1 25 | $-53.4M | $49.6M | ||
| Q4 24 | $19.3M | $-6.2M | ||
| Q3 24 | — | $14.1M | ||
| Q2 24 | $-8.4M | $-38.0M | ||
| Q1 24 | $-133.3M | $60.2M |
| Q4 25 | -7.1% | 2.6% | ||
| Q3 25 | 23.6% | -11.5% | ||
| Q2 25 | 2.5% | -25.7% | ||
| Q1 25 | -32.0% | 14.6% | ||
| Q4 24 | 9.1% | -1.9% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | -4.2% | -15.5% | ||
| Q1 24 | -77.3% | 16.2% |
| Q4 25 | 0.1% | 2.3% | ||
| Q3 25 | 0.0% | 2.5% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 1.5% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 2.4% |
| Q4 25 | — | 2038.00× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SPWH
暂无分部数据
